Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION: ONC201 in Newly Diagnosed H3 K27M-mutant Diffuse Glioma
NCT05580562Phase 3Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jan 2023
- Primary completion
- Jun 2028
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 18
01
Overview
A Phase 3 trial of dordaviprone in Diffuse Glioma (DG), sponsored by Jazz Pharmaceuticals plc. Started Jan 2023; status: recruiting.
02
Drugs
dordaviprone
03
Conditions
Diffuse Glioma (DG)
Beyond the preview
Go deeper on NCT05580562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580562.